Abstract
DUSP22, an atypical dual-specificity phosphatase enzyme, plays a significant role in regulating multiple kinase signaling pathways by dephosphorylation. Our study demonstrated that decreased DUSP22 expression is associated with shorter disease-free survival, advanced TNM (tumor, lymph nodes, and metastasis), cancer stage, and higher tumor grade in lung adenocarcinoma (LUAD) patients. Exogenous DUSP22 expression reduces the colony-forming capacity of lung cancer cells and inhibits xenograft tumor growth primarily by targeting EGFR and suppressing its activity through dephosphorylation. Knockdown of DUSP22 using shRNA enhances EGFR dependency in HCC827 lung cancer cells and increases sensitivity to gefitinib, an EGFR inhibitor. Consistently, genetic deletion of DUSP22 enhances EGFRdel (exon 19 deletion)-driven lung tumorigenesis and elevates EGFR activity. Pharmacological inhibition of DUSP22 activates EGFR, ERK1/2, and upregulates downstream PD-L1 expression. Additionally, lentiviral deletion of DUSP22 by shRNA enhances lung cancer cell migration through EGFR/c-Met and PD-L1-dependent pathways. Gefitinib, an EGFR inhibitor, mechanistically suppresses migration induced by DUSP22 deletion and inhibits c-Met activity. Furthermore, cabozantinib, a c-Met inhibitor, reduces migration and attenuates EGFR activation caused by DUSP22 deletion. Collectively, our findings support the hypothesis that loss of DUSP22 function in lung cancer cells confers a survival advantage by augmenting EGFR signaling, leading to increased activation of downstream c-Met, ERK1/2, and PD-L1 axis, ultimately contributing to the progression of advanced lung cancer.
Similar content being viewed by others
Introduction
Genetic alterations in the EGFR gene lead to abnormal activation of multiple oncogenic signaling pathways, resulting in tumorigenesis and supporting EGFR’s tumor-promoting function in various cancers [1,2,3,4]. Studies have shown that transgenic expression of EGFR mutants in mouse lung tissue induces the development of lung adenocarcinoma, and treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs) leads to significant tumor regression [5], indicating that activating mutations in the EGFR tyrosine kinase domain increase EGFR activity and accelerate lung tumorigenesis. Interestingly. prolonged activation of EGFR enhances the dependence of lung tumor cells on EGFR signaling [6]. Additionally, several members of the EGFR family are often co-expressed with the RTK c-Met in various human cancers, and c-Met supports the proliferation and survival of non-small cell lung cancer (NSCLC) cells [7]. Increased EGFR/c-Met signaling in lung cancer patients is associated with shorter survival, suggesting that the interplay between EGFR and c-Met signaling plays a crucial role in lung tumor progression and development of resistance to TKI treatments [8].
Recently, a group of dual-specificity phosphatases (DUSPs) has emerged as critical regulators of multiple signaling pathways by dephosphorylating and thereby inactivating or activating MAPKs [9]. The majority of research has focused on understanding how aberrant MAPK signaling facilitates the development and progression of cancer [10]. Additionally, malfunctioning phosphatases contribute to tumorigenesis and resistance by allowing uncontrolled kinase activation [11]. For example, loss of phosphatase and tensin homolog (PTEN) expression in lung cancer cells leads to resistance to the TKI erlotinib by activating EGFR and Akt kinases [12]. We postulated that when negative regulators, such as inhibitory phosphatases of EGFR, are lost, it leads to abnormal activation of EGFR for amplifying EGFR-driven oncogenic processes. DUSP22 (also referred to as JKAP or LMW-DSP2) is classified as an atypical member within the DUSP family of phosphatases due to its absence of a MAP kinase-interacting motif [13]. Previous studies have demonstrated that DUSP22 plays a significant role in regulating various signaling proteins, including estrogen receptor α (ERα), MAPKs, STAT3, FAK, and Lck [14,15,16,17,18,19]. Through dephosphorylation, DUSP22 modulates the activity of these molecules, indicating its ability to govern multiple signaling pathways in different cell types. Abnormal expression of certain DUSPs has been observed in various cancers [20,21,22]. Notably, studies have revealed down-regulation of DUSP22 expression in breast cancer, anaplastic large cell lymphoma, peripheral T-cell lymphoma, and colorectal cancer [23,24,25,26]. Previously, we identified DUSP22 as a negative regulator of the EGFR-androgen receptor (AR) signaling pathway in prostate cancer cells through dephosphorylation [27]. Based on these findings, it is reasonable to explore whether the same regulatory connection between DUSP22 and EGFR plays a significant role in repressing the development and progression of EGFR-driven lung cancer. We hypothesized that DUSP22 is a crucial phosphatase for controlling EGFR signaling and that the loss of DUSP22 function may accelerate the development of EGFR-driven lung tumors.
In this study, we showed that DUSP22 expression was significantly reduced in LUAD tissues compared to non-tumor tissues. Furthermore, we found that DUSP22 expression played a role in suppressing the growth and migration of lung tumor cells by inhibiting EGFR/c-Met signaling and its downstream signaling molecules. Remarkably, our analysis of The Cancer Genome Atlas (TCGA) LUAD datasets using bioinformatics analysis revealed that patients with low DUSP22 expression had poorer disease-free survival. The results support our hypothesis that the phosphatase activity of DUSP22 inhibits EGFR/c-Met signaling and underscore the important role of DUSP22 in suppressing EGFR signaling to prevent lung tumor formation.
Results
Low DUSP22 expression in lung cancer tissues of LUAD patients correlates with shorter disease-free survival
We first determined the clinical significance of DUSP22 expression in LUAD patients by analyzing multiple publicly accessible LUAD datasets, including TCGA, using web tools such as the Kaplan-Meier plotter (http://kmplot.com/analysis/) and the OncoLnc web site (http://www.oncolnc.org/) [28,29,30]. Our data showed that LUAD patients with low DUSP22 expression exhibited notably reduced disease-free survival across multiple LUAD datasets (Fig. 1A, B, and Fig. S1A–C). However, we did not observe a significant correlation between the expression of DUSP22 and the prognosis of lung squamous cell carcinoma (LUSC) patients (Fig. S1D). The expression of DUSP22 exhibited a significant decrease in LUAD tissues when compared to adjacent normal tissues (Fig. 1C). Additionally, low expression of DUSP22 was significantly associated with various clinicopathological parameters, such as tumor stage, TNM cancer stage, and tumor grade (Fig. 1D and Table 1), suggesting that decreased DUSP22 expression could be a key factor in the initiation and advancement of LUAD.
Next, we conducted gene correlation analysis and Hallmark GSEA with genes that exhibited a negative correlation with DUSP22 expression in the TCGA LUAD patient dataset to identify enriched signaling pathways. The pathways showing the most significant enrichment were marked by increased expression of E2F target genes, progression of the cell cycle, and genes involved in DNA repair (Fig. 1E). We have identified a specific set of cell cycle genes that show a direct correlation with low DUSP22 expression in LUAD patients (Fig. S1E). These cell cycle genes have been linked to unfavorable prognosis outcomes in various types of cancer [31]. Taken together, the results of our bioinformatics analysis indicate that DUSP22 has the potential to serve as a biomarker for predicting disease progression and adverse prognosis in LUAD patients.
The EGFR signaling pathway is inhibited by DUSP22, leading to the inhibition of lung cancer cell growth
To investigate how DUSP22 suppresses lung cancer development and progression, we stably introduced wild-type DUSP22 expression into various human and mouse lung cancer cell lines (HCC827, H1650, LL/2, H520, and TC-1) because lung cancer cells typically exhibit low endogenous levels of DUSP22 protein expression (Fig. S2A). Exogenous DUSP22 expression was found to inhibit colony formation in multiple lung cancer cell lines, including HCC827, H1650, and LL/2 (Fig. 2A, B), indicating a suppressive role of DUSP22 in lung tumorigenesis. Considering the dephosphorylation function of DUSP22, we performed a phosphokinase array to identify kinases in both HCC827 (gefitinib-sensitive) and H1650 (gefitinib-resistant) lung cancer cells in the presence or absence of DUSP22 shRNA (± gefitinib for HCC827). EGFR was identified as the primary target of DUSP22 in both HCC827 and H1650 lung cancer cells. (Fig. 2C, D, and Fig. S2B). Importantly, our data revealed a consistent dephosphorylation-based regulation between DUSP22 and EGFR in different lung cancer cell lines harboring wild-type (WT) or mutant EGFR genes (Fig. 2D and Fig. S2C).
To confirm the link between DUSP22-induced growth inhibition and EGFR in lung cancer cells, we assessed the colony-forming capacity of EGFRlow H520 and TC-1 cancer cells in the presence or absence of DUSP22 expression (Fig. S2A). Significantly, DUSP22 failed to inhibit colony formation in EGFRlow H520 and TC-1 cells (Fig. S2D), suggesting that DUSP22 predominantly acts on EGFR and hinders EGFR signaling to impede lung cancer cell proliferation via dephosphorylation, regardless of their EGFR mutation status. Western blot analysis confirmed that introducing DUSP22 resulted in a significant decrease in pEGFR and pERK1/2 levels in HCC827 and H1650 lung cancer cells (Fig. S2E, F). Notably, DUSP22 expression had a minimal effect on pAkt levels in both cell lines (Fig. S2E, F). These findings provide evidence for the role of DUSP22 in regulating the EGFR/ERK signaling pathway in lung cancer cells harboring constitutively-active EGFR mutations.
Next, we conducted colony formation assays to investigate the impact of DUSP22 deletion on the tumorigenicity of HCC827 lung cancer cells in response to gefitinib. Surprisingly, we observed a notable decrease in the colony forming ability of DUSP22-deleted HCC827 lung cancer cells when treated with gefitinib at a concentration of 10 nM (Fig. 2E, F), suggesting that higher EGFR activity in DUSP22-deleted HCC827 lung cancer cells may make them more vulnerable to EGFR TKI treatment. Unexpectedly, when gefitinib was absent, the deletion of DUSP22 expression had an adverse effect on the colony-forming ability and proliferation of HCC827 cells (Fig. 2E and Fig. S2G), implicating that maintaining functional DUSP22 expression is crucial for regulating the activity of substrate kinases, preventing the occurrence of undesired toxicity caused by the hyperactivation of downstream kinases [32].
Genetic ablation of DUSP22 in mice results in acceleration of EGFRdel-driven lung tumorigenesis
Our next investigation delved into the role of DUSP22 in EGFRdel-induced lung tumorigenesis in vivo by breeding EGFRdel transgenic mice, where EGFRdel expression is controlled by the lung-specific surfactant protein C (SPC) promoter, with DUSP22 Wild-type (WT) or DUSP22 knockout (KO) mice to generate EGFR-del/DUSP22 WT and EGFR-del/DUSP22 KO mice [19, 33]. During the observation period of 6 to 18 months, we closely monitored the occurrence of lung tumors in mice of both EGFRdel/DUSP22 WT and KO mice. Our findings showed that the absence of DUSP22 led to a significant acceleration in the formation of lung tumors driven by transgenic EGFRdel expression (Fig. 3A, B, and Fig. S3A). We consistently observed increased phosphorylation of EGFR (Tyr1068) in lung tissues of EGFRdel/DUSP22 KO mice compared to those of EGFRdel/DUSP22 WT mice (Fig. 3C). We assessed the effect of DUSP22 deletion on the response of murine lung tumor cells to gefitinib by treating DUSP22 WT and KO mice with gefitinib for 14 days. Western blot analysis of lung tissue lysates showed that gefitinib effectively reduced pEGFR levels in both EGFRdel/DUSP22 KO and EGFRdel/DUSP22 WT mice (Fig. S3B), indicating that DUSP22-deficient lung tumor cells remained sensitive to gefitinib treatment.
Next, we examined the tumor immune microenvironment in EGFRdel/DUSP22 KO mice by comparing lung tumors with EGFRdel/DUSP22 KO and EGFRdel control mice. Our analysis revealed a notable reduction in CD8+ T cells, NKT cells, and tumor IFNγ levels in EGFRdel/DUSP22 KO tumors (Figs. 3D, E, F, and S3C). These findings align with a study by Akaby et al., indicating that constitutive EGFR activation in mouse lung tumors correlates with increased immunosuppressive gene signatures [34]. We postulated that the deletion of DUSP22 in the epithelial or stromal compartments of lung tissues in EGFRdel/DUSP22 KO mice may accelerate EGFRdel-driven lung tumorigenesis. To pinpoint the specific compartment responsible for this enhancement, we established a syngeneic lung tumor model using TC-1 cells implanted subcutaneously in WT and DUSP22 KO mice. TC-1 tumor growth in DUSP22-deficient mice showed no significant difference compared to WT mice (Fig. 3G), suggesting that DUSP22 ablation in immune cells or stromal cells does not significantly promote lung tumor growth in vivo. These findings support the idea that tumor-intrinsic DUSP22 function is crucial in suppressing EGFRdel-driven lung tumorigenesis. In a previous study, PTEN deletion in H1650 cancer cells led to continuous Akt activation, providing a growth advantage even under EGFR inhibition [12]. To assess the impact of DUSP22 expression in suppressing the EGFR/ERK signaling pathway on the growth of EGFR-TKI-resistant H1650 cells with sustained Akt activation, we observed a significant inhibitory effect of DUSP22 on H1650 xenograft tumor growth in SCID (severe combined immunodeficiency disease) mice (Fig. 3H, I), suggesting that DUSP22-mediated inhibition of the EGFR pathway at multiple levels could be highly effective against TKI-resistant PTEN-deleted H1650 cells. Collectively, our data support a role for DUSP22 in the suppression of tumor development in lung cancer cells through the dephosphorylation of key target kinases in the EGFR signaling pathway.
DUSP22 inhibits cancer cell migration through targeting the crosstalk between EGFR and c-Met signaling
Prior research has shown that DUSP22 can inhibit the migration of H1299 lung cancer cells with wild-type EGFR by dephosphorylating FAK, a non-receptor tyrosine kinase [18]. We then investigated if deleting DUSP22 would enhance the migration of HCC827 lung cancer cells by boosting EGFR activity. Deletion of DUSP22 using lentiviral shRNA notably increased the migration of HCC827 cells, which was reduced by gefitinib treatment (Fig. 4A). This implies that constitutively-active EGFR mutants can promote lung cancer cell migration, partly through the enhanced EGFR activity resulting from DUSP22 deletion. Additionally, DUSP22 deletion markedly increased p-FAK (Tyr397) levels in HCC827 cells, which were not directly related to cell migration as they persisted at higher levels following gefitinib treatment (Fig. 4B). Importantly, a previous study supports the crucial role of c-Met in cell migration and invasion driven by activated EGFR [8]. We investigated how c-Met affects cell migration in response to DUSP22 deletion using cabozantinib, a c-Met inhibitor [35]. Cabozantinib significantly reduced DUSP22 deletion-induced cell migration (Fig. 4C), highlighting the importance of c-Met in regulating cell migration induced by DUSP22 deletion. Combining gefitinib and cabozantinib did not further suppress DUSP22 deletion-induced cell migration (Fig. 4C), suggesting a potential mutual dependence or redundancy in EGFR and c-Met RTK activation after DUSP22 depletion, jointly controlling cell migration. To explore this further, we showed that gefitinib and cabozantinib individually inhibit EGFR and c-Met activity (Fig. 4D). Gefitinib reduced pc-Met levels, while cabozantinib decreased pEGFR levels in DUSP22-deleted HCC827 cells (Fig. 4D). Cabozantinib effectively inhibited DUSP22 deletion-induced cell migration but increased FAK Tyr397 phosphorylation (Fig. 4D). Cabozantinib did not suppress colony-forming ability in DUSP22-depleted HCC827 cells (Fig. S3D), suggesting a crosstalk between EGFR and c-Met signaling that predominantly facilitates cell migration after DUSP22 deletion in HCC827 cells.
DUSP22 functions as a negative regulator of PD-L1, a downstream target of EGFR signaling
PTEN loss enhances cancer cell immune evasion by upregulating PD-L1 expression [36]. One study demonstrated that mutated EGFR (T790M/L858R)-driven lung tumors can suppress host immunity via PD-1/PD-L1 pathways [34]. The interplay of DUSP22 with EGFR and PD-L1 in lung cancer cells remains unclear. Using a DUSP22 inhibitor, BML260 [37], we examined its impact on EGFR signaling and PD-L1 levels. BML260-mediated inhibition of DUSP22 function increased pEGFR, pERK1/2, pSTAT3, as well as PD-L1 protein expression (Fig. 5A, left panel). Knockdown of DUSP22 by shRNA in H1650 cells similarly elevated levels of these signaling molecules (Fig. 5A, right panel), suggesting a link between DUSP22, EGFR signaling, and PD-L1 expression. In addition, DUSP22 deletion induces PD-L1 upregulation in lung cancer cells, as confirmed by FACS analysis (Fig. 5B).
Upregulated PD-L1 expression was observed in EGFRlow TC-1 cell expressing human EGFRdel (Fig. 5C). Knockdown of DUSP22 increased PD-L1 expression in TC-1 cells with or without EGFRdel, but enhanced EGFR signaling in TC-1-EGFRdel cells (Figs. 5C and S4A). Notably, DUSP22 deletion did not affect PD-L2 expression in HCC827 or H1650 cells (Fig. S4B). These results indicate that DUSP22 regulates the PD-L1 expression in lung cancer cells via EGFR-dependent and independent pathways, beyond its role in EGFR suppression for cell growth. Next, we established clinical significance of DUSP22 relative to PD-L1 expression in the TCGA LUAD dataset. Decreased DUSP22 expression was associated with significantly higher PD-L1 levels in LUAD patients (Fig. 5D, p = 0.00405). No correlation was found between DUSP22 and PD-L2 in the same dataset (Fig. S4C). These findings suggest that DUSP22 expression may serve as a predictive marker for PD-L1 expression, reflecting the influence of EGFR-dependent or independent pathways modulated by DUSP22.
DUSP22 suppresses PD-L1 expression via inhibition of EGFR/c-Met and their downstream signaling pathways
To investigate the molecular link between DUSP22 deletion and increased PD-L1 expression in lung cancer cells, we found that PD-L1 levels decreased significantly in DUSP22-deleted HCC827 cells treated with gefitinib or cabozantinib alone (Fig. 6A), suggesting that the upregulation of PD-L1 due to DUSP22 deletion is mediated through EGFR and c-Met pathways. By treating DUSP22-deleted HCC827 cells with various inhibitors, we identified that gefitinib, Stattic, and U0126 effectively reduced PD-L1 levels induced by DUSP22 deletion, but LY294002 (PI3K/Akt inhibitor) did not (Fig. 6B, C). These findings underscore the crucial role of DUSP22 in negatively regulating the EGFR downstream pathway and suppressing PD-L1 expression. In contrast, inhibitors except for Sttatic were ineffective in reducing PD-L1 expression induced by DUSP22 deletion in gefitinib-resistant H1650 cells (Fig. S5A–C), suggesting that the activation of STAT3 due to DUSP22 deletion did not contribute to Akt-mediated resistance in H1650 cells. Additionally, DUSP22 deletion did not affect the sensitivity of these cells to gefitinib and cabozantinib. However, it did moderately suppress colony formation and proliferation in H1650 cells (Fig. S6A–C). These results indicate that PTEN deletion-induced gefitinib resistance in H1650 cells through sustained Akt activity may serve as a common resistance mechanism to inhibitors targeting EGFR downstream signaling for cell survival and gene expression [12]. More importantly, studies have shown that tumoral PD-L1 plays a role in controlling tumor cell motility for spread [38, 39]. To investigate the impact of PD-L1 neutralization on HCC827 cancer cell migration heightened by DUSP22 deletion, we performed a cell migration assay with and without an anti-PD-L1 antibody (Atezolizumab). The findings demonstrated that the anti-PD-L1 antibody effectively inhibited HCC827 cancer cell migration induced by DUSP22 deletion (Fig. 6D). Together, our results suggest that DUSP22 negatively regulates cell migration through EGFR/c-Met and PD-L1-dependent pathways.
Discussion
Recent studies indicate that protein phosphatases play a crucial role in regulating kinase pathways in various cancer cells, functioning either as tumor suppressors or oncogenes by dephosphorylation processes [40]. For example, genetic changes affecting PTEN can drive lung tumorigenesis by activating mTOR/Akt pathways, leading to lung cancer metastasis [41]. Notably, PTEN is a significant prognostic marker for lung cancer patients, with loss of PTEN function linked to poorer outcomes [42]. Here, we investigated the role of DUSP22 in lung cancer development by studying its function in suppressing hyperactive EGFR signaling, a key oncogenic driver in LUAD [43]. Our study showed that DUSP22 acts as an EGFR phosphatase in lung cancer cells, inhibiting EGFR activity and its crosstalk with c-Met. This novel mechanism hinders crucial processes like cancer cell proliferation, migration, and PD-L1 expression. Additionally, studies have shown that PTEN loss results in sustained Akt and EGFR activation, providing a survival advantage and potential resistance to EGFR inhibitors in lung cancer cells [12, 44]. In contrast, DUSP22 deletion enhances HCC827 cell sensitivity to gefitinib, suggesting that DUSP22 loss promotes EGFR dependence in lung cancer, and targeting EGFR could be a more effective therapeutic approach for DUSP22-deficient lung tumors. Enforced DUSP22 expression significantly suppresses the growth of erlotinib-resistant H1650 lung cancer cell-based tumor by inhibiting EGFR and downstream ERK1/2 while not affecting sustained Akt activity. Targeting the EGFR/ERK1/2 axis through DUSP22 may combat PTEN deletion-induced EGFR TKI resistance. Our results support a combined EGFR and ERK1/2 targeting strategy for overcoming resistance in EGFR TKI-resistant lung cancer, as demonstrated in one recent study [45].
Unexpectedly, depleting DUSP22 revealed a toxicity mechanism driven by active ERK1/2, causing growth arrest in HCC827 and H1650 cells. This is consistent with one study on DUSP6, highlighting the importance of another DUSP enzymes in regulating ERK1/2 to prevent cell death induced by aberrant ERK1/2 activation in lung cancer [32]. These results challenge the idea that ERK1/2 activation due to DUSP downregulation drives treatment resistance and tumor progression. DUSP6 research emphasizes the need for tight control over the DUSP6/ERK1/2 axis to prevent hyperactivity-related toxicity and support tumor cell functions [32]. DUSP22 deletion in lung cancer cells increases dependence on EGFR activity for growth and survival, as it leads to co-activation of EGFR and ERK1/2. Proper regulation of ERK1/2 by DUSP enzymes is crucial to avoid detrimental consequences of unchecked ERK1/2 activity.
Previously, Li et al. showed that DUSP22 inhibits H1299 cell migration through FAK dephosphorylation [18]. However, the increase in FAK activity by EGFR or c-Met inhibitors does not align with the suppression of cell migration by both inhibitors, indicating FAK may not drive EGFR or c-Met-mediated migration [8]. Studies have indicated that gefitinib and cabozantinib activate FAK through various pathways, such as osteopontin induction and integrin signaling [46, 47]. Our study excludes FAK involvement in DUSP22 deletion-induced cell migration. The inhibition of cell migration and signaling induced by DUSP22 deletion by gefitinib and cabozantinib supports a working model where EGFR and c-Met RTKs exhibit mutual dependence following DUSP22 depletion. Consistently, treatment with gefitinib or cabozantinib markedly reduced PD-L1 expression in HCC827 cells with DUSP22 deletion, linking PD-L1 upregulation to increased cell migration in DUSP22-deleted lung cancer cells. Therefore, combining EGFR or c-Met TKIs with anti-PD1/PD-L1 immunotherapy for DUSP22-depleted EGFRdel-driven mouse lung tumors appears promising. However, several clinical trials have not shown significant benefits from PD-1/PD-L1 blockade alone or with an EGFR TKI in EGFR mutant lung cancer patients [48]. Further study is necessary to discover improved treatment strategies for EGFR mutant lung cancer patients with DUSP22 loss or downregulation. Here, we have developed a working model demonstrating that DUSP22 negatively regulates cell growth and migration in lung cancer cells through EGFR/c-Met and PD-L1-dependent pathways (Fig. 6E).
In summary, our study has provided insights into the tumor-intrinsic mechanisms of DUSP22 in suppressing lung cancer via EGFR. Our bioinformatics data suggest that LUAD patients with low DUSP22 expression had a worse prognosis, which may be potentially associated with increased EGFR/c-Met signaling, leading to further activation of downstream signaling and driving lung cancer cell growth, migration/invasion, and PD-L1 upregulation. Future translational studies are needed to test TKIs of EGFR/c-Met and PD-L1 blockade to inhibit lung cancer progression resulting from loss of DUSP22 function. Lastly, the mRNA-lipid nanoparticle (LNP) technology has emerged as the leading method for gene delivery, primarily due to the successful development of COVID-19 vaccines [49]. By utilizing synthetic mRNA encoding DUSP22 and coating it with LNP, it becomes possible to directly deliver DUSP22 to lung cancer cells that lack sufficient levels of this gene. This approach has the potential to harness DUSP22 expression, enabling the simultaneous targeting of EGFR and ERK1/2 pathways, resulting in the suppression of TKI-resistant or DUSP22-deleted tumor growth.
Material and methods
Cell culture and chemicals
A549, H1299, HCC827, H1650, H1975, TC-1, H520, LK2, and LL/2 cells (originally from ATCC) were obtained from the NHRI cell line bank, verified by cell line authentication using STR (short tandem repeat) DNA genotyping, and cultured in RPMI 1640 medium (#11875-093; Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal calf serum (10437-028; Gibco, Thermo Fisher Scientific, Waltham, MA, USA), 2 mM L-Glutamine (#GLL01; Caisson Laboratories, Smithfield, UT, USA), and 1% penicillin/streptomycin (#15140-122; Gibco, Thermo Fisher Scientific, Waltham, MA, USA). Cell lines were routinely confirmed to be free of mycoplasma contamination using PCR analysis. For in vitro treatment, BML260 (#141733; Abcam, Cambridge, UK), gefitinib (#ab142052; Abcam, Cambridge, UK), LY294002 (#1130; Tocris Bioscience, Bristol, UK), Stattic (#S7024; Selleck Chemicals LLC, Houston, TX, USA), U0126 (#1144; Tocris Bioscience, Bristol, UK), and cabozantinib (#S1119; Selleck Chemicals LLC, Houston, TX, USA) were each dissolved in DMSO (#D2650; Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) and stored at −2 °C; DMSO was used as vehicle control.
Statistics analysis and reproducibility
The lung adenocarcinoma dataset from TCGA (https://cancergenome.nih.gov/) was analyzed with R/Bioconductor. Survival analysis of this dataset was performed using OncoLnc (http://www.oncolnc.org/) [30] and Kaplan-Meier plotter [50]. The log-rank test was used for Kaplan–Meier survival analyses. RNA sequencing data were retrieved and analyzed to identify genes positively and negatively correlated with DUSP22 expression. Identified genes were sent for functional enrichment analysis on The Database for Annotation, Visualization and Integrated Discovery (DAVID; https://david.ncifcrf.gov/) [51, 52]. The Cox proportional hazards regression model was used to perform univariate and multivariate survival analysis using R. The TNM staging system is used for staging LUAD patients: T (tumor) describes the size and extent of the primary tumor, and the number after T (TX-T4) refers to the tumor size and/or extent of the main tumor; N (lymph node) indicates whether cancer has spread to nearby lymph nodes, and the number after N (NX-N3) provides information about the number of affected lymph nodes; M (metastasis) indicates whether the cancer has metastasized or spread to distant organs or tissues beyond the primary site, and the number after M (MX-M1) determine the presence or absence of distant metastases. Stage I, II, III, and IV were used to classify the extent and progression of cancer. Each stage represents a different level of tumor growth, invasion, and spread. Prism v.7.0. software (GraphPad Software, San Diego, CA, USA) was used for graphs and statistical analyses. Each experiment in this study was performed more than three times with similar results, and the data presented in figures are representative of multiple independent experiments. Differences between two groups of data were determined using the Student’s t test or the Wilcoxon Rank Sum Test. For comparison of more than two groups, one-way or two-way analysis of variance (ANOVA) were used for statistical analysis. p values less than 0.05 were considered statistically significant. Not significant: n.s, *p < 0.05; **p < 0.01; ***p < 0.001.
A detailed description of the materials and methods used in this study is available in the online Supplementary Material.
Data availability
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. All data generated or analyzed during this study are included in this published article and its supplementary figure files.
References
Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006;9:485–95.
Buckley AF, Burgart LJ, Sahai V, Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol. 2008;129:245–51.
Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014;4:1269–80.
Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials. 2013;34:8690–707.
Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 2006;20:1496–510.
Farnsworth DA, Chen YT, de Rappard Yuswack G, Lockwood WW. Emerging molecular dependencies of mutant EGFR-driven non-small cell lung cancer. Cells. 2021;10:3553.
Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005;65:1479–88.
Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGF-independent potentiation of EGFR action by c-Met. Oncogene. 2011;30:3625–35.
Patterson KI, Brummer T, O’Brien PM, Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J. 2009;418:475–89.
Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37:543–50.
Stebbing J, Lit LC, Zhang H, Darrington RS, Melaiu O, Rudraraju B, et al. The regulatory roles of phosphatases in cancer. Oncogene. 2014;33:939–53.
Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009;69:3256–61.
Huang CY, Tan TH. DUSPs, to MAP kinases and beyond. Cell Biosci. 2012;2:24.
Sekine Y, Ikeda O, Hayakawa Y, Tsuji S, Imoto S, Aoki N, et al. DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118. Oncogene. 2007;26:6038–49.
Shen Y, Luche R, Wei B, Gordon ML, Diltz CD, Tonks NK. Activation of the Jnk signaling pathway by a dual-specificity phosphatase, JSP-1. Proc Natl Acad Sci USA. 2001;98:13613–8.
Chen AJ, Zhou G, Juan T, Colicos SM, Cannon JP, Cabriera-Hansen M, et al. The dual specificity JKAP specifically activates the c-Jun N-terminal kinase pathway. J Biol Chem. 2002;277:36592–601.
Sekine Y, Tsuji S, Ikeda O, Sato N, Aoki N, Aoyama K, et al. Regulation of STAT3-mediated signaling by LMW-DSP2. Oncogene. 2006;25:5801–6.
Li JP, Fu YN, Chen YR, Tan TH. JNK pathway-associated phosphatase dephosphorylates focal adhesion kinase and suppresses cell migration. J Biol Chem. 2010;285:5472–8.
Li JP, Yang CY, Chuang HC, Lan JL, Chen DY, Chen YM, et al. The phosphatase JKAP/DUSP22 inhibits T-cell receptor signalling and autoimmunity by inactivating Lck. Nat Commun. 2014;5:3618.
Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007;448:807–10.
Bermudez O, Pages G, Gimond C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol. 2010;299:C189–202.
Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 2008;27:253–61.
Bernard-Pierrot I, Gruel N, Stransky N, Vincent-Salomon A, Reyal F, Raynal V, et al. Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res. 2008;68:7165–75.
Feldman AL, Dogan A, Smith DI, Law ME, Ansell SM, Johnson SH, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117:915–9.
Melard P, Idrissi Y, Andrique L, Poglio S, Prochazkova-Carlotti M, Berhouet S, et al. Molecular alterations and tumor suppressive function of the DUSP22 (Dual Specificity Phosphatase 22) gene in peripheral T-cell lymphoma subtypes. Oncotarget. 2016;7:68734–48.
Yu D, Li Z, Gan M, Zhang H, Yin X, Tang S, et al. Decreased expression of dual specificity phosphatase 22 in colorectal cancer and its potential prognostic relevance for stage IV CRC patients. Tumour Biol. 2015;36:8531–5.
Lin HP, Ho HM, Chang CW, Yeh SD, Su YW, Tan TH, et al. DUSP22 suppresses prostate cancer proliferation by targeting the EGFR-AR axis. FASEB J. 2019;33:14653–67.
Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS ONE. 2013;8:e82241.
Cline MS, Craft B, Swatloski T, Goldman M, Ma S, Haussler D, et al. Exploring TCGA pan-cancer data at the UCSC cancer genomics browser. Scientific Reports. 2013;3:2652.
Anaya J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput Sci. 2016;2:e67.
Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938–45.
Unni AM, Harbourne B, Oh MH, Wild S, Ferrarone JR, Lockwood WW, et al. Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. Elife. 2018;7:e33718.
Yang CH, Chou HC, Fu YN, Yeh CL, Cheng HW, Chang IC, et al. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82. Biochim Biophys Acta. 2015;1852:1540–9.
Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355–63.
Padda S, Neal JW, Wakelee HA. MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl Lung Cancer Res. 2012;1:238–53.
Vidotto T, Melo CM, Castelli E, Koti M, Dos Reis RB, Squire JA. Emerging role of PTEN loss in evasion of the immune response to tumours. Br J Cancer. 2020;122:1732–43.
Ju A, Cho S-Y. Inhibition of dual-specificity phosphatase 22 (DUSP22) by PRL-3 inhibitor I. Bull Korean Chem Soc. 2012;33:3142–44.
Eichberger J, Schulz D, Pscheidl K, Fiedler M, Reichert TE, Bauer RJ, et al. PD-L1 influences cell spreading, migration and invasion in head and neck cancer cells. Int J Mol Sci. 2020;21:8089–104.
Wang M, Xiong C, Mercurio AM. PD-L1 promotes rear retraction during persistent cell migration by altering integrin beta4 dynamics. J Cell Biol. 2022;221:e202108083.
Meeusen B, Janssens V. Tumor suppressive protein phosphatases in human cancer: Emerging targets for therapeutic intervention and tumor stratification. Int J Biochem Cell Biol. 2018;96:98–134.
Gkountakos A, Sartori G, Falcone I, Piro G, Ciuffreda L, Carbone C, et al. PTEN in lung cancer: dealing with the problem, building on new knowledge and turning the game around. Cancers. 2019;11:1141.
Yanagawa N, Leduc C, Kohler D, Saieg MA, John T, Sykes J, et al. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. J Thorac Oncol. 2012;7:1513–21.
da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49–69.
Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci USA. 2010;107:6459.
Ku BM, Heo JY, Kim J, Sun JM, Lee SH, Ahn JS, et al. ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer. Investig New Drugs. 2022;40:265–73.
Fu Y, Zhang Y, Lei Z, Liu T, Cai T, Wang A, et al. Abnormally activated OPN/integrin alphaVbeta3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer. J Hematol Oncol. 2020;13:169.
Wang DD, Chen Y, Chen ZB, Yan FJ, Dai XY, Ying MD, et al. CT-707, a novel FAK inhibitor, synergizes with cabozantinib to suppress hepatocellular carcinoma by blocking cabozantinib-induced FAK activation. Mol Cancer Ther. 2016;15:2916–25.
Ding J, Ding X, Leng Z. Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance. Expert Rev Anticancer Ther. 2023;23:187–98. 1-12
Xu X, Xia T. Recent advances in site-specific lipid nanoparticles for mRNA delivery. ACS Nanosci Au. 2023;3:192–203.
Nagy A, Lanczky A, Menyhart O, Gyorffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8:9227.
Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1–13.
Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57.
Acknowledgements
This work was supported by grants from the National Science and Technology Council (NSTC, 110-2314-B-400-044 to WJL), and the National Health Research Institutes (13A1-IMPP05-014 to WJL) in Taiwan. We thank the pathology laboratory of the Core Instrument Center at the National Health Research Institutes for providing technical support for our H&E and immunohistochemistry experiments and for lung pathology consultation. CW Chang is a recipient of an NSTC postdoctoral fellowship (105-2811-B-400-014), and HH Lin is a recipient of an NSTC postdoctoral fellowship (110-2811-B-400-524). We also thank Dr. Loretta Collins of WriteScience, LLC for manuscript editing and proofreading.
Author information
Authors and Affiliations
Contributions
HHL, CWC, YTL, HPL, HMH, CHC, and LMC performed experiments, analyzed the data, prepared the figures. SDY, HFJ, YRC, THT, and YWS performed discussion, and contributed new reagents, mouse lines, and tools. WJL provide funding, designed and supervised the experiments, interpreted data, wrote, revised, and finalized the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Lin, HH., Chang, CW., Liao, YT. et al. DUSP22 inhibits lung tumorigenesis by suppression of EGFR/c-Met signaling. Cell Death Discov. 10, 285 (2024). https://doi.org/10.1038/s41420-024-02038-8
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41420-024-02038-8
- Springer Nature Limited